Arcutis Biotherapeutics, Inc.: stock overview

ARQTNASDAQHealthcare · Pharmaceutical Preparations

Price

$28.26

November 13, 2026Market cap $3.5B

DCF calculator

What Ploutos Investor adds for Arcutis Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Arcutis Biotherapeutics had revenue of $509M over the last 12 months and net income of $30M, a net margin of 5.9%. At $28.26 the shares trade at a P/E of 117.2. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$3.5B
124M shares
P/E
117.2
Revenue, 12 months
$509M
Net margin
5.9%
2025: -4.3%, above 49% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+151.2% a year over 2 years

Fiscal years in figures

ARQT's revenue, profit, cash flow and dividend with each year-end price, from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.7B
$3.5B
Enterprise value 
–
P/E 
117.2
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 10.5
14.4
FCF yield 3-year median: -6.8%
1.7%
Earnings yield 3-year median: -8.3%
0.9%

Profitability

Gross margin 
91.2%
Operating margin 
6.9%
Net margin 3-year median: -71.3%
5.9%
ROIC 
9.0%
ROIC, 5-year average 
-41.9%
ROE 
14.9%

Growth

Revenue, yearly change 
+91.3%
EPS, yearly change 
–
FCF, yearly change 
–

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$259M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
2.6x
Current ratio 
2.92

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+4.6%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-3.3%

Above 50% of the 285 companies in its industry, and 28% of all.

Net margin

-4.3%

Above 49% of the 302 companies in its industry, and 25% of all.

ROE

-8.5%

Above 45% of the 267 companies in its industry, and 20% of all.

ROA

-3.7%

Above 46% of the 313 companies in its industry, and 23% of all.

Revenue growth

91.3%

Above 93% of the 292 companies in its industry, and 98% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Arcutis Biotherapeutics, Inc.
CIK
1787306
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
124M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Arcutis Biotherapeutics's filings show?

These are Arcutis Biotherapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ARQT

Didn't find what you were looking for?

Ask us
What is ARQT's market cap?

Arcutis Biotherapeutics, Inc.'s market cap is $3.5B, at a price of $28.26 on November 13, 2026 and 124M shares.

What is ARQT's P/E?

ARQT's P/E is 117.2, on earnings per share of $0.24 over the last 12 months.

How much revenue does ARQT have?

Arcutis Biotherapeutics had revenue of $509M over the last 12 months.

Does ARQT pay a dividend?

No. Arcutis Biotherapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.